Safe utilization of ruxolitinib in simultaneous primary myelofibrosis and warm autoimmune hemolytic anemia. Pope V, Hsia CC. Ann Hematol 2023 Nov 6. doi: 10.1007/s00277-023-05535.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Pope V, Hsia CC. Safe utilization of ruxolitinib in simultaneous primary myelofibrosis and warm autoimmune hemolytic anemia. Ann Hematol 2023 Nov 6. doi: 10.1007/s00277-023-05535.
PMID: 37930364